These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 31705351

  • 1. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska T, Brunton VG.
    Breast Cancer Res Treat; 2020 Feb; 179(3):543-555. PubMed ID: 31705351
    [Abstract] [Full Text] [Related]

  • 2. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA.
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [Abstract] [Full Text] [Related]

  • 3. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.
    Breast Cancer Res; 2014 Jan 23; 16(1):R9. PubMed ID: 24451154
    [Abstract] [Full Text] [Related]

  • 4. Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
    Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.
    Oncotarget; 2016 Mar 08; 7(10):11539-52. PubMed ID: 26883193
    [Abstract] [Full Text] [Related]

  • 5. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
    Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D.
    Cell Res; 2014 May 08; 24(5):542-59. PubMed ID: 24675532
    [Abstract] [Full Text] [Related]

  • 6. Increased autophagy blocks HER2-mediated breast tumorigenesis.
    Vega-Rubín-de-Celis S, Zou Z, Fernández ÁF, Ci B, Kim M, Xiao G, Xie Y, Levine B.
    Proc Natl Acad Sci U S A; 2018 Apr 17; 115(16):4176-4181. PubMed ID: 29610308
    [Abstract] [Full Text] [Related]

  • 7. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.
    J Natl Cancer Inst; 2017 Nov 01; 109(11):. PubMed ID: 29059433
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.
    Breast Cancer Res; 2014 May 05; 16(3):R45. PubMed ID: 24887236
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
    Huang WC, Hung CM, Wei CT, Chen TM, Chien PH, Pan HL, Lin YM, Chen YJ.
    Oncotarget; 2016 Sep 20; 7(38):62352-62363. PubMed ID: 27694691
    [Abstract] [Full Text] [Related]

  • 15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 20; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 16. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.
    Mol Cancer Ther; 2012 Sep 20; 11(9):1978-87. PubMed ID: 22761403
    [Abstract] [Full Text] [Related]

  • 17. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
    Chintalaramulu N, Vadivelu R, Nguyen NT, Cock IE.
    Inflammopharmacology; 2020 Oct 20; 28(5):1375-1386. PubMed ID: 32378049
    [Abstract] [Full Text] [Related]

  • 18. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.
    Clin Cancer Res; 2012 May 01; 18(9):2603-12. PubMed ID: 22407832
    [Abstract] [Full Text] [Related]

  • 19. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ.
    Oncogene; 2016 Jul 07; 35(27):3607-12. PubMed ID: 26500061
    [Abstract] [Full Text] [Related]

  • 20. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
    Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA.
    Mol Biol Cell; 2015 Nov 05; 26(22):3946-53. PubMed ID: 26337386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.